ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 69 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $237,000 | +7.7% | 45,900 | -11.4% | 0.00% | – |
| Q2 2021 | $220,000 | +197.3% | 51,800 | +275.4% | 0.00% | – |
| Q1 2021 | $74,000 | -68.0% | 13,800 | +76.9% | 0.00% | – |
| Q4 2020 | $231,000 | +272.6% | 7,800 | 0.0% | 0.00% | – |
| Q3 2020 | $62,000 | -47.5% | 7,800 | -33.9% | 0.00% | – |
| Q2 2020 | $118,000 | +637.5% | 11,800 | +100.0% | 0.00% | – |
| Q1 2020 | $16,000 | +128.6% | 5,900 | 0.0% | 0.00% | – |
| Q4 2019 | $7,000 | – | 5,900 | +3370.6% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 170 | -91.1% | 0.00% | – |
| Q2 2019 | $8,000 | 0.0% | 1,900 | 0.0% | 0.00% | – |
| Q1 2019 | $8,000 | +60.0% | 1,900 | +100.0% | 0.00% | – |
| Q4 2018 | $5,000 | -61.5% | 950 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | +18.2% | 950 | 0.0% | 0.00% | – |
| Q2 2018 | $11,000 | 0.0% | 950 | 0.0% | 0.00% | – |
| Q1 2018 | $11,000 | +83.3% | 950 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | – | 950 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |